Review
Oncology
Bruce D. Cheson, Grzegorz Nowakowski, Gilles Salles
Summary: Newer, more effective and non-cytotoxic therapies are needed for patients with DLBCL and other B-cell malignancies. Approved treatments include various combinations of drugs, CAR-T cell products, and ongoing development of other therapies. Combinations of targeted therapies are expected to further improve the outcomes for patients.
BLOOD CANCER JOURNAL
(2021)
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Review
Medicine, General & Internal
Eva Gonzalez Barca
Summary: This article describes new promising therapies that are in clinical development to treat relapsed/refractory DLBCL, including CAR T-cell and monoclonal antibody therapies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Stefano Poletto, Mattia Novo, Luca Paruzzo, Pio Manlio Mirko Frascione, Umberto Vitolo
Summary: Diffuse large B-cell lymphoma (DLBCL) is a curable disease but a significant proportion of patients are unresponsive or relapse. New treatment options such as CAR-T have shown promising results for relapsed/refractory DLBCL. Efforts to improve frontline treatment have not been successful so far. Preliminary data on personalized therapy based on different molecular subtypes of DLBCL are encouraging.
CANCER TREATMENT REVIEWS
(2022)
Review
Hematology
Eliza A. Hawkes, Allison Barraclough, Laurie H. Sehn
Summary: Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, has a good prognosis in limited-stage DLBCL (LS-DLBCL) patients. Recent studies have provided new insights and strategies for the treatment of LS-DLBCL, including the use of PET scans and clinical trials. However, there is currently no standard definition for LS-DLBCL, and treatment strategies vary across studies, posing challenges in interpretation.
Article
Medicine, General & Internal
Eric S. Geanes, Stacey A. Krepel, Rebecca McLennan, Stephen Pierce, Santosh Khanal, Todd Bradley
Summary: The study shows that bispecific antibodies targeting CD74 and IL4R on the surface of lymphoma cells could provide improved defense against rituximab resistance.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Fang Hu, Huan Li, Lei Li, Robert Peter Gale, Yuanbin Song, Shuiqin Chen, Yang Liang
Summary: Research has found that some cells in diffuse large B-cell lymphoma have the genotype of a stem cell, which is correlated with immune and stromal cell scores, patients' progression-free survival, and overall survival. Additionally, CDC7 expression is correlated with the degree of stemness, and CDC7 inhibitors show potential in inhibiting lymphoma growth.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Immunology
Suheil Albert Atallah-Yunes, Michael J. Robertson, Utpal P. Dave, Paola Ghione, Fabiana Perna
Summary: The prognosis for patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have shown promising results, but there is a need for further development of novel therapies to improve outcomes for non-responsive or relapsed patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yan Liang, Zhuo-Jun Yu, Min Liu, Hui-Min Liu, Tao Xiong, Yuan-Yan Tang, Zhi-Ping Huang
Summary: DLBCL is the most common type of non-Hodgkin lymphoma worldwide. Hsa-miR-429 exerts a tumor-suppressive effect by targeting CBX8, which promotes cancer development. Hsa-miR-429 may be a potential diagnostic marker and nucleic acid drug for DLBCL, while CBX8 represents a promising therapeutic target.
MOLECULAR MEDICINE REPORTS
(2021)
Article
Cell Biology
Eva A. M. Hesius, Lidia van Laar, Margriet Oosterveld, Annemiek B. van Spriel, Blanca Scheijen, Jan Willem Leeuwis, Henri A. M. Marres, Patricia J. T. A. Groenen, Wendy B. C. Stevens, Ellen van Der Spek, Adriaan J. C. van den Brule, Brigiet M. Hoevenaars, Konnie M. Hebeda, Michiel van den Brand
Summary: LBCL-IRF4 is a newly identified subtype of large B cell lymphoma in the 2017 revised WHO classification, initially reported in children. This study aimed to assess the frequency of IRF4 rearrangements in adult DLBCLs that need to be reclassified as LBCL-IRF4 using FISH. Among 238 DLBCL patients, six (including the index patient) were found to have IRF4 rearrangements, and their immunohistochemical profile was consistent with LBCL-IRF4. This study highlights the importance of considering LBCL-IRF4 in older patients and at different anatomical sites.
Review
Biotechnology & Applied Microbiology
Prokop Vodicka, Pavel Klener, Marek Trneny
Summary: Genetic alterations in lymphoma cells serve as the basis for targeted therapy, but further research and clinical trials are needed to improve the survival rates of high-risk subsets of patients.
ONCOTARGETS AND THERAPY
(2022)
Review
Oncology
Allison Barraclough, Eliza Hawkes, Laurie H. Sehn, Sonali M. Smith
Summary: Large B-cell lymphoma is the most common lymphoma and has the highest burden of lymphoma-related deaths. Treatment has aimed to achieve a cure with CHOP and rituximab plus CHOP, but not all patients are cured due to the heterogeneity of the disease.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Husain Yar Khan, Md. Hafiz Uddin, Suresh Kumar Balasubramanian, Noor Sulaiman, Marium Iqbal, Mahmoud Chaker, Amro Aboukameel, Yiwei Li, William Senapedis, Erkan Baloglu, Ramzi M. Mohammad, Jeffrey Zonder, Asfar S. Azmi
Summary: Targeting PAK4 and NAMPT using the small molecule inhibitor KPT-9274 can inhibit cell proliferation, deplete energy, and induce apoptosis in various NHL subtypes. KPT-9274 treatment shows potent anti-tumor effects in experimental models, suggesting its potential as a novel therapy for NHL.
Review
Oncology
Natalia Yanguas-Casas, Lucia Pedrosa, Ismael Fernandez-Miranda, Margarita Sanchez-Beato
Summary: Lymphoma research integrates basic and applied research, providing insights for targeted therapies and personalized medicine through genomics studies on DLBCL. The genetic complexity and epigenetic alterations make precision medicine challenging for lymphoma patients, requiring further research to improve treatment options.
Article
Radiology, Nuclear Medicine & Medical Imaging
M. S. Lim, Thomas Beyer, A. Babayan, M. Bergmann, M. Brehme, A. Buyx, J. Czernin, G. Egger, K. S. J. Elenitoba-Johnson, B. Gueckel, A. Jacan, H. Haslacher, R. J. Hicks, L. Kenner, M. Langanke, M. Mitterhauser, B. J. Pichler, H. R. Salih, R. Schibli, S. Schulz, J. Simecek, J. Simon, M. O. Soares, U. Stelzl, W. Wadsak, K. Zatloukal, M. Zeitlinger, M. Hacker
MOLECULAR IMAGING AND BIOLOGY
(2020)
Article
Oncology
Carlos Murga-Zamalloa, Delphine C. M. Rolland, Avery Polk, Ashley Wolfe, Hiran Dewar, Pinki Chowdhury, Ozlem Onder, Rajan Dewar, Noah A. Brown, Nathanael G. Bailey, Kedar Inamdar, Megan S. Lim, Kojo S. J. Elenitoba-Johnson, Ryan A. Wilcox
CLINICAL CANCER RESEARCH
(2020)
Review
Pathology
Noah A. Brown, Kojo S. J. Elenitoba-Johnson
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 15, 2020
(2020)
Article
Biochemistry & Molecular Biology
Soumya S. Rajan, Amit Dipak Amin, Lingxiao Li, Delphine C. Rolland, Haiquan Li, Deukwoo Kwon, Mercedes F. Kweh, Artavazd Arumov, Evan R. Roberts, Aimin Yan, Venkatesha Basrur, Kojo S. J. Elenitoba-Johnson, Xi Steven Chen, Soham D. Puvvada, Yves A. Lussier, Daniel Bilbao, Megan S. Lim, Jonathan H. Schatz
Article
Oncology
Rizwan Saffie, Nan Zhou, Delphine Rolland, Ozlem Onder, Venkatesha Basrur, Sydney Campbell, Kathryn E. Wellen, Kojo S. J. Elenitoba-Johnson, Brian C. Capell, Luca Busino
Article
Oncology
Danilo Fiore, Luca Vincenzo Cappelli, Paul Zumbo, Jude M. Phillips, Zhaoqi Liu, Shuhua Cheng, Liron Yoffe, Paola Ghione, Federica Di Maggio, Ahmet Dogan, Inna Khodos, Elisa de Stanchina, Joseph Casano, Clarisse Kayembe, Wayne Tam, Doron Betel, Robin Foa, Leandro Cerchietti, Raul Rabadan, Steven Horwitz, David M. Weinstock, Giorgio Inghirami
Article
Multidisciplinary Sciences
Biljana Culjkovic-Kraljacic, Lucy Skrabanek, Maria V. Revuelta, Jadwiga Gasiorek, Victoria H. Cowling, Leandro Cerchietti, Katherine L. B. Borden
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Hematology
Frits van Rhee, Eric Oksenhendler, Gordan Srkalovic, Peter Voorhees, Megan Lim, Angela Dispenzieri, Makoto Ide, Sophia Parente, Stephen Schey, Matthew Streetly, Raymond Wong, David Wu, Ivan Maillard, Joshua Brandstadter, Nikhil Munshi, Wilbur Bowne, Kojo S. Elenitoba-Johnson, Alexander Fossa, Mary Jo Lechowicz, Shanmuganathan Chandrakasan, Sheila K. Pierson, Amy Greenway, Sunita Nasta, Kazuyuki Yoshizaki, Razelle Kurzrock, Thomas S. Uldrick, Corey Casper, Amy Chadburn, David C. Fajgenbaum
Article
Immunology
Yong Du, Ling Lei, Huihua Ding, Yanping Chen, Simanta Pathak, John Hicks, Phuongthy T. Tran, Minghua Wu, Betty Chang, Uwe Wirtz, Chandra Mohan
Summary: This study demonstrates that the inhibition of Bruton tyrosine kinase (Btk) has therapeutic and preventative effects in multiple models of end-organ inflammation, including lupus nephritis, anti-GBM nephritis, systemic sclerosis-like skin disease, and bleomycin-induced lung disease. BTK inhibitors effectively reduce renal damage and proteinuria in lupus nephritis, as well as skin thickness, fibrosis, collagen deposition, and inflammation in systemic sclerosis-like disease. Additionally, the inhibition of Btk results in decreased lung inflammatory cell infiltration. These findings have important implications for the management of systemic rheumatic diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biology
Daniel P. Gomari, Annalise Schweickart, Leandro Cerchietti, Elisabeth Paietta, Hugo Fernandez, Hassen Al-Amin, Karsten Suhre, Jan Krumsiek
Summary: Variable autoencoders offer a powerful method for learning biologically meaningful, non-linear, and transferable latent representations of metabolomics data.
COMMUNICATIONS BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mehdi Ghram, Gavin Morris, Biljana Culjkovic-Kraljacic, Jean-Clement Mars, Patrick Gendron, Lucy Skrabanek, Maria Victoria Revuelta, Leandro Cerchietti, Monica L. Guzman, Katherine L. B. Borden
Summary: Aberrant splicing, a known contributor to malignancies, is usually attributed to splice-factor mutation. This study, however, discovered a mutation-independent mechanism for extensively reprogramming alternative splicing (AS) in acute myeloid leukemia (AML). The dysregulated expression of eukaryotic translation initiation factor eIF4E was found to increase selective splice-factor production, thereby affecting multiple spliceosome complexes and generating a splicing landscape that supported altered splice-site selection for hundreds of transcripts in AML patients with high-eIF4E expression.
Article
Oncology
Meng Li, Matthew R. Teater, Jun Young Hong, Noel R. Park, Cihangir Duy, Hao Shen, Ling Wang, Zhengming Chen, Leandro Cerchietti, Shawn M. Davidson, Hening Lin, Ari M. Melnick
Summary: This study reveals the link between SIRT3 and ATF4 in DLBCL cells, connecting lymphoma amino acid metabolism with ATF4 translation via metabolic stress signals. The SIRT3-ATF4 axis is required in DLBCL cells regardless of subtype, indicating a common metabolic vulnerability in DLBCLs and can serve as a therapeutic target.
BLOOD CANCER DISCOVERY
(2022)
Article
Cell Biology
Sheila K. Pierson, Johnson S. Khor, Jasira Ziglar, Amy Liu, Katherine Floess, Erin NaPier, Alexander M. Gorzewski, Mark-Avery Tamakloe, Victoria Powers, Faizaan Akhter, Eric Haljasmaa, Raj Jayanthan, Arthur Rubenstein, Mileva Repasky, Kojo Elenitoba-Johnson, Jason Ruth, Bette Jacobs, Matthew Streetly, Linus Angenendt, Jose Luis Patier, Simone Ferrero, Pier Luigi Zinzani, Louis Terriou, Corey Casper, Elaine Jaffe, Christian Hoffmann, Eric Oksenhendler, Alexander Fossa, Gordan Srkalovic, Amy Chadburn, Thomas S. Uldrick, Megan Lim, Frits van Rhee, David C. Fajgenbaum
CELL REPORTS MEDICINE
(2020)
Article
Genetics & Heredity
Lauren M. Chunn, Diane C. Nefcy, Rachel W. Scouten, Ryan P. Tarpey, Gurinder Chauhan, Megan S. Lim, Kojo S. J. Elenitoba-Johnson, Steven A. Schwartz, Mark J. Kiel
FRONTIERS IN GENETICS
(2020)
Article
Hematology
Joi Ninomoto, Ahmad Mokatrin, Taisei Kinoshita, Carol Marimpietri, Terrance D. Barrett, Betty Y. Chang, Juthamas Sukbuntherng, Danelle F. James, Mark Crowther